Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and around 16% over the past month, inviting closer scrutiny from investors.

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

The University of Pennsylvania, biotech firm BioNTech, and Osage University Partners, a venture capital firm in Bala Cynwyd, ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

A key enabler for BioNTech's ambitious plans is an exceptionally strong balance sheet, rare for a biotechnology company. As of the end of 2025, the Mainz-based firm reported liquid funds of ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.